Spire Health Announces First Patients Enrolled in University of Rochester Medical Center’s A-SPIRE Heart Failure Study Using Health Tags
First of its kind study to evaluate the use of wearable sensors in heart failure patients to identify physiological markers which may predict readmission
Spire Health, the leading digital healthcare company for continuous respiratory and pulse rate remote patient monitoring, and the University of Rochester Medical Center (URMC), one of the nation’s leading academic medical centers, today announced the first patients have been enrolled in the A-SPIRE Heart Failure (HF) study using Spire Health Tags.
The goal of A-SPIRE HF study (Utilizing Physiologic Information from Spire Health Tags to Identify Heart Failure Patients At-Risk for Hospital Readmission) is to evaluate the use of wearable physiological sensors from Spire Health to identify heart failure patients at-risk of hospital readmission. URMC investigators will enroll 100 heart failure patients at their time of discharge from the hospital in the A-SPIRE HF study. Enrolled patients will be provided Spire Health Tags to continuously monitor their respiration, pulse rate, and activity including sleep patterns and stress levels for 30 days. Study investigators will analyze the physiological data collected from the wearable sensors for patients 30 days post-discharge with the goals of determining patient adherence to monitoring and identifying potential physiological markers that could predict risk of readmission. Potential future phases of the study will evaluate the predictive power of the sensors over extended periods of time and assess the efficacy of interventions to reduce 30-day readmission rates.
“Nationwide, about one quarter of the patients diagnosed with heart failure are readmitted to the hospital within 30 days, a significant burden for patients we want to avoid whenever possible. We believe that continuous monitoring of patient physiology, as is being tested in the A-SPIRE HF study will help us identify potential risk markers for rehospitalization, in an effort to build effective readmission prevention programs in the future,” said Valentina Kutyifa, M.D., Ph.D., Associate Professor, Department of Medicine, Cardiovascular Research Center, University of Rochester Medical Center, Principal Investigator of the A-SPIRE HF study.
“We are proud to partner with URMC for the innovative A-SPIRE HF study. We feel strongly that the capture of continuous physiological data will allow care teams to monitor patients’ health much more closely and allow earlier intervention to avoid rehospitalization,” said Phil Golz, Vice President Commercial, Spire Health. “Our sensors are designed to be 100% passive and do not require any change in patient behavior or daily interaction; this drives strong compliance to use of the sensors over extended periods and the possibility to obtain comprehensive and actionable clinical data. The Spire remote patient monitoring platform is used primarily by pulmonologists to monitor patients with COPD; but, given the high co-morbidity levels of patients with cardiac disease, there is strong potential for their expanded use in other conditions.”
To learn more about URMC’s A-SPIRE study visit: https://clinicaltrials.gov/ct2/show/NCT04550052
